To investigate the intervention effects of Astragalus polysaccharide on peritoneal fibrosis related to peritoneal dialysis in mice and its possible mechanisms.

Male C57BL/6 mice were randomly divided into a blank control group (Control), a model group (Model), a low-dose group of Astragalus polysaccharide (APS 100 mg/kg) and a high-dose group of Astragalus Polysaccharide (APS 200 mg/kg), with 10 mice in each group. A mouse model of peritoneal fibrosis was established using high-glucose peritoneal dialysis fluid, and the treatment was administered daily for 28 days. After the final treatment, peritoneal function (glucose transport and urea nitrogen levels) was assessed. Hematoxylin-eosin staining (HE) and Masson staining were performed to observe the pathological changes, fibrosis and peritoneal thickness. Western blot analysis was conducted to detect the expressions of epithelial-mesenchymal transition (EMT) related proteins in peritoneal tissue. The immunohistochemistry and flow cytometry methods were used to assess the expressions of macrophage polarization-related proteins in peritoneal tissue.

Compared to the Control group, the Model group showed significant increases in peritoneal thickness and collagen fiber deposition, elevated glucose transport and higher urea nitrogen levels. The expressions of EMT-related proteins[α-smooth muscle actin (α-SMA), collagen Ⅲ, fibronectin)]significantly increased, while E-cadherin protein expression significantly decreased, and M2 macrophage markers[Arginase-1 (Arg-1), CD163]were significantly elevated. In comparison to the Model group, the treatment with Astragalus polysaccharide led to significant improvements in the above indicators, with the high-dose group showing better effects than the low-dose group. After the clearance of macrophages, the inhibitory effect of Astragalus polysaccharide on the peritoneal fibrosis was weakened.

Astragalus polysaccharide inhibits the peritoneal fibrosis in mice by suppressing epithelial-mesenchymal transition and regulating M2 macrophage polarization.

To observe the regulatory mechanism of Yupingfeng Powder (玉屏风散) on “activation of Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway inhibiting fibroblast autophagy in pulmonary fibrosis”, and to explore the mechanism of Yupingfeng Powder in improving idiopathic pulmonary fibrosis (IPF).

Forty-eight Sprague Dawley (SD) rats were randomly divided into 8 groups with 6 rats in each, including blank group, sham-operated group, model group, positive control (prednisone) group, STAT3 inhibitor (sorafenib) group and Yupingfeng Powder high, middle and low dose groups. The rats in the model group and in each administration group were injected with bleomycin (BLM) intratracheally to establish the lung fibrosis model. Gastric administration was started after the 14th day of modeling, and prednisone [6 mg/ (kg·d)]was given to the positive control group, sorafenib[30 mg/ (kg·d)]was given to the STAT3 inhibitor group, and Yupingfeng Powder solution was given to the high dose group[6 g/ (kg·d)], the middle dose group[3 g/ (kg·d)]and the low dose group[1.5 g/ (kg·d)], respectively. The equal volume of saline was given to the blank group and the model group. The drug was continuously administered until the 30th day. The symptoms and signs, the changes in lung tissue morphology, the α-smooth muscle actin (α-SMA) protein expression, the levels of interleukin-6 (IL-6), transforming growth factor-β1 (TGF-β1), JAK2/STAT3 signaling pathway and respective phagocytosis index in lung tissues were observed before and after treatment.

Compared with the blank and sham-operated groups, the model group showed severe symptoms, signs and lung tissue injury status, significantly higher levels of IL-6 andTGF-β1 (P<0.01), significantly higher expressions of α-SMA, JAK2, phosphorylated Janus kinase 2 (p-JAK2), STAT3, phosphorylation signal transducer and activator of transcription 3 (p-STAT3) proteins (P<0.01) and myeloid cell leukemia 1 (Mcl-1) protein and mRNA (P<0.01). The protein and mRNA expressions of Beclin1, phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) and Atg14 were significantly reduced (P<0.01), the binding between Beclin1 and Mcl-1 was significantly enhanced, and fibroblast autophagy was significantly reduced. After treatment, compared with those in the model group, all the indexes of the rats in the high and middle dose groups of Yupingfeng Powder, prednisone group and sorafenib group were significantly improved (P<0.01 or P<0.05), the binding between Beclin1 and Mcl-1 was significantly weakened, and the autophagy of fibroblasts was significantly increased, while the indicators of the low dose group basically showed no significant changes. Overall, the efficacy of the high dose group of Yupingfeng Powder was better than that of the middle and low dose groups, and equal to that of the prednisone group and close to that of the sorafenib group.

Yupingfeng Powder is able to reduce collagen fiber deposition by increasing fibroblast autophagy to inhibit pulmonary fibrosis, and this process may be related to the inhibition of the phosphorylation and activation of the JAK2/STAT3 pathway by decreasing the levels of IL-6 and TGF-β1, thus blocking the binding of Mcl-1 to Beclin1, further increasing the formation of type Ⅲ PI3K complex, and enhancing the ability of Beclinl to activate autophagy.

To study the clinical observation of the effect of Modified Yangyin Qingfei Decoction (养阴清肺汤加减) combined with voice training on postoperative benign lesions of vocal cords.

A total of 200 patients with benign vocal cord lesions treated in the hospital from From January 2022 to June 2024 were selected as the study objects, and the patients were divided into two groups by random number table method, 100 cases in each group. The patients receiving voice training were established as the control group, and those receiving voice training combined with Modified Yangyin Qingfei Decoction were established as the observation group. After treatment, the clinical effect, clinical symptom score, voice acoustic index and voice disorder index scale score (VHI-10) of the two groups were observed and compared.

The total effective rate of the observation group was 98.00%, higher than that of the control group (P<0.05). After treatment, the clinical symptom score of the observation group was lower than that of the control group (P<0.05). After treatment, the clinical signs in the observation group were lower than those in the control group (P<0.05). After treatment, the VHI-10 score of the observation group was lower than that of the control group (P<0.05). Compared with those in the control group, the Jitter and Shimmer were lower and the maximum phonation time (MPT) was higher in the observation group (P<0.05).

Voice training combined with Modified Yangyin Qingfei Decoction can effectively improve the clinical effect, reduce the clinical symptoms and signs, improve the voice disorder and promote the recovery of the patients, and has high clinical application value.

To analyze the effect of Modified Huangqi Jianzhong Decoction (黄芪建中汤加减) combined with quadruple therapy on gastric motility and ulcer healing in patients with Helicobacter pylori (Hp) positive gastric ulcer of deficiency-cold in spleen-stomach type.

Two hundred patients with Hp-positive gastric ulcer of deficiency-cold in spleen-stomach type admitted to Henan Provincial Hospital of Traditional Chinese Medicine from July 2020 to June 2023 were divided into combined group (100 cases) and control group (100 cases) by simple random sampling. Both groups were treated with quadruple therapy, and the combined group was treated with Modified Huangqi Jianzhong Decoction for 2 months. The changes of gastric motility function, ulcer healing and TCM syndrome integral between the two groups before and after treatment were compared, and the Hp clearance rate, recurrence rate and clinical efficacy of the two groups were compared.

After treatment, the gastric emptying time, gastric antrum contraction frequency and gastric antrum-duodenum coordination in the two groups decreased, and the gastric antrum contraction amplitude increased. After treatment, the gastric emptying time, antrum contraction frequency and antrum-duodenum coordination in the combined group were lower than those in the control group, and the antrum contraction amplitude was higher than that in the control group (P<0.05). After treatment, the area of thick moss at the bottom of ulcer, the area of congestion of surrounding mucosa and the area of regenerative epithelium in the two groups decreased compared with those before treatment. And these indexes in the combined group were lower than those in the control group (P<0.05). After treatment, the main symptom score, secondary symptom score and total score of TCM syndromes in the two groups decreased compared with those before treatment and these indexes in the combined group were lower than those in the control group (P<0.05). The clearance rate and recurrence rate of Hp in the combined group were lower than those in the control group (P<0.05). After 2 months of treatment, the total effective rate of the combined group was higher than that of the control group (P<0.05).

On the basis of quadruple therapy, Modified Huangqi Jianzhong Decoction can not only promote the improvement of gastric motility and ulcer healing, but also be beneficial to reduce TCM syndrome scores, improve the Hp clearance rate, prevent the recurrence of Hp infection and improve the clinical efficacy.

To evaluate the effect of Zuogui Wan (左归丸, ZGW) on reducing ovarian toxicity of Tripterygium glycosides (TG) and to explore its attenuated mechanism by proteomic methods.

Thirty-two 2-month-old female SD rats with SPF grade were randomly divided into control (CON) group (10 rats) and model group (22 rats). The model group rats were given continuous intragastatic administration of TG (50 mg·kg^-1·d^-1) for 2 weeks to construct the ovarian injury model. The rats with successful model (20) were randomly divided into TG group and ZGW group (1.875 g·kg^-1·d^-1) with 10 rats in each group. The estrus cycle of the rats was measured during continuous gavage for 4 weeks. After gavage, the body weight, ovarian and uterine indexes were measured, and serum sex hormone levels were determined by enzyme-linked immunosorbent assay (ELISA). Hematoxylin-eosin (HE) staining was used to observe the pathological damage of ovarian tissue, and label free quantitative proteomic analysis was performed. Western Blot was used to verify the protein expression of the enrichment pathway.

ZGW could effectively regulate the estrous cycle and sex hormone level of TG-induced female rats, and significantly reduce the production of atretic follicles (P<0.000 1). Proteomics showed that compared with those in the CON group, there were 203 differential proteins in the TG group, and 28 differential proteins were significantly reduced after TG treatment. KEGG enrichment analysis involved signaling pathways such as sphingolipid biosynthesis, glycosaminoglycan degradation, degradation of other glycans and cell apoptosis. Western Blot results showed that ZGW could down-regulate the expressions of Cycs, Parp3, Bax and Caspase-3 and up-regulate the expression of Bcl-2 protein in apoptosis signaling pathway.

ZGW can regulate the apoptosis signaling pathway mediated by Cycs, Parp3, Bax, Caspase-3 and Bcl-2 and plays a role in alleviating the damage of ovarian tissue caused by TG.

To investigate the sensitization effect of traditional Chinese medicine compound Huangjing (Polygonati Rhizoma) and Huangqin (Scutellariae Radix) on the anti-tumor effect of cisplatin (DDP), and further investigate its potential mechanism.

A subcutaneous tumor model of lung cancer in mice was constructed, and Huangjing (Polygonati Rhizoma) -Huangqin (Scutellariae Radix) (HH), DDP and HH combined DDP (HH+DDP) were administered to observe the changes in tumor volume in mice. Lewis cell lines were cultured in vitro, and the corresponding interventions were applied to detect the cell proliferation activity, apoptosis, reactive oxygen species (ROS) production, as well as the changes in mitochondrial membrane potential.

In vitro and in vivo results showed that the HH+DDP group significantly inhibited the growth and proliferation of LLC cell lines compared to the DDP group and HH group. After the intervention in the HH+DDP group, the ratio of apoptotic protein related proteins Bax and Bcl-2 increased, and the expression of Caspase-3 was up-regulated, promoting the apoptosis and inhibiting the tumor cell proliferation. At the same time, it was also found that the HH+DDP group had a significant inhibitory effect on nuclear factor-κB (NF-κB) /inhibitor of NF-κB (IκB-α). Flow cytometry revealed higher levels of apoptosis and ROS production in the HH+DDP group. In addition, the HH+DDP group also reduced mitochondrial membrane potential and promoted the apoptosis.

HH combined DDP can significantly enhance its anti-tumor sensitivity and induce apoptosis through mitochondrial related apoptosis pathways, inhibiting tumor cell proliferation in vitro and in vivo.

To explore the mechanism of verbascoside (VB) on dopamine cell protection in the mice with Parkinson's disease (PD).

A total of 63 C57/BL male mice were enrolled as the experimental subjects and randomly divided into blank control group, 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) group, 10 mg/kg group, 30 mg/kg group, 60 mg/kg group, 120 mg/kg group and 180 mg/kg group, with 9 mice in each group. After successful modeling, the behavioral changes of the mice were evaluated by mining, climbing pole and hanging experiments. Hematoxylin-eosin (HE) and Nissl staining were used to evaluate the neuron counts in the substantia nigra of the mice. Immunohistochemistry method and immunofluorescence staining were used to evaluate the tyrosine hydroxylase (TH) -positive and positive cell counts in the substantia nigra, respectively. Western blotting was used to detect the expression of TH protein in the substantia nigra of the mice. HE staining was used to evaluate liver and kidney cell morphology and cell count. Finally, the optimal dose group screened for proteomic analysis was performed.

(1) In the mine experiment, the total distance and the distance of the 120 mg/kg group were higher than those of the MPTP group and other concentration gradient groups (all P<0.05). In the pole climbing experiment, the pole climbing time of the 120 mg/kg group was both higher than that of the MPTP group and other concentration gradient groups (all P<0.05). In the pole climbing experiment, the pole climbing time of the 120 mg/kg group was both higher than that of the pole climbing experiment. The suspension scores of the MPTP group and the other concentration gradient groups (all P<0.05). In the suspension experiment, the suspension scores of the 120 mg/kg group were higher than those of the MPTP group and the 10 mg/kg group (all P<0.05). (2) In HE staining, Niss-type staining and immunohistochemistry method, the cell count and tan pixel proportion of the 120 mg/kg group were higher than those of the MPTP group and other concentration gradient groups (all P<0.05). (3) In immunofluorescence, the average fluorescence intensity of the 120 mg/kg group was higher than that of the MPTP group and other concentration gradient groups (all P<0.05). (5) In Western blotting, the relative expression of TH in the 120 mg/kg group was higher than that in the MPTP group and other concentration gradient groups (all P<0.05). (6) Proteomic analysis showed that compared with the 120 mg/kg group and the MPTP group, there were 181 proteins with statistical differences, including 83 up-regulated proteins and 98 down-regulated proteins. There were up to 85 differential proteins localized to the nucleus of subcellular nucleus, and gene ontology (GO) functional analysis showed that there were up to 6 biological processes directly related to immunity (BP). KEGG pathway analysis showed the highest level of enrichment with arginine biosynthesis (all P<0.05).

VB with the dose of 120 mg/kg has a protective effect on DA neurons in PD mice, and this protective effect may be related to a variety of biological processes including arginine biosynthesis.

To study the clinical efficacy of Liumo Zengye Decoction (六磨增液汤) in the treatment of opioid-related constipation in patients with cancer pain.

A total of 86 cancer pain patients with opioid-related constipation treated in the hospital from January 2022 to May 2023 were included. According to the random number table method, they were divided into observation group and control group, with 43 patients in each group. The patients in the control group were treated with thunder fire moxibustion and acupoint application. The observation group was treated with Liumo Zengye Decoction combined with thunder fire moxibustion and acupoint application. The course of treatment was 14 days. The efficacy, TCM symptom scores, first defecation time after administration, disappearance time of abdominal pain and distension, toilet time, Chinese version of Constipation Patient Quality of Life Scale (PAC-QOL) score and adverse reactions were compared between the two groups.

The total effective rate of the observation group was 97.67%, which was significantly higher than that of the control group (81.40%) (P<0.05). After treatment, the scores of dry stool, red tongue, less body fluid and less moss and fatigue in the two groups were significantly decreased (P<0.05). After treatment, the scores of the above symptoms in the observation group were significantly lower than those in the control group (P<0.05). The first defecation time, abdominal pain and bloating disappearance time and toilet time in the observation group were significantly shorter than those in the control group (P<0.05). After treatment, the scores of each dimension and total score of PAC-QOL scale in the two groups were significantly decreased (P<0.05). After treatment, the scores of physiology, satisfaction and total score of PAC-QOL scale in the observation group were significantly lower than those in the control group (P<0.05), while the scores of social psychology and concern dimension were not significantly different from those in the control group (P>0.05). The incidence of adverse reactions in the observation group and the control group was 11.63% and 6.98%, respectively, and there was no significant difference between the two groups (P>0.05).

The clinical efficacy of Liumo Zengye Decoction combined with thunder fire moxibustion and acupoint application in the treatment of opioid-related constipation in the patients with cancer pain is satisfactory. It can better improve various symptoms, promote rapid recovery of the body, and improve the quality of life of the patients. It is a safe and effective treatment plan.

To research the therapeutic effects of Modified Guishen Wan (归肾丸化裁) on rat model of polycystic ovary syndrome (PCOS) by regulating Toll-like receptor 4 (TLR4) /nuclear factor-κB (NF-κB) signaling pathway, particularly its impact on ovarian function, serum hormone levels and inflammatory factor expression.

Forty 8-week-old SPF female SD rats with normal estrous cycle were randomly divided into four groups (n＝10) : normal group, model group, Modified Guishen Wan group and positive drug group (metformin). Except for the normal group, the other groups were administered letrozole via gavage for 21 consecutive days to establish the PCOS model. The Modified Guishen Wan group and the positive drug group received the corresponding treatments for 21 days. After the experiment, the estrous cycle, ovarian index, serum sex hormone levels, serum inflammatory factor levels, the mRNA levels of inflammation-related genes in ovarian tissue and protein expression were detected to evaluate the efficacy of the Modified Guishen Wan.

The estrous cycle of the normal group was 3-5 days/cycle. After 21 days of modeling, the estrous cycles of the other groups became disordered, with an average of 5-8 days/cycle, mostly in the interphase or prophase, and some lacked a complete estrous cycle, indicating ovarian damage. After 3 weeks of gavage treatment, the estrous cycles of the positive group and the Modified Guishen Wan group recovered. Compared with that of the normal group, the ovarian index of the model group significantly increased (P<0.01). Compared with that of the model group, the ovarian index of the rats of the Modified Guishen Wan group and the positive drug group significantly decreased (P<0.01), approaching the normal group levels. The ovarian tissue of the model group showed multiple cystic changes, with reduced or absent corpora lutea. In contrast, the Modified Guishen Wan group and the positive drug group had fewer cystic and atretic follicles, and the granulosa cell layer structure tended to be normal. The levels of testosterone (T) and luteinizing hormone (LH) in the model group were significantly higher (P<0.01, P<0.05), while follicle-stimulating hormone (FSH) levels were significantly lower (P<0.05). The Modified Guishen Wan group and the positive drug group could significantly reduce the levels of T and LH (P<0.05), and the Modified Guishen Wan group and the positive drug group could also significantly increase the FSH levels (P<0.05). Compared with those of the normal group, the serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1 β (IL-1β) in the model group were significantly elevated (P<0.001). Compared with the model group, both the Modified Guishen Wan and the positive drug could significantly reduce the serum levels of TNF-α, IL-6 and IL-1β in PCOS rats (P<0.01 and P<0.05). Compared with those of the normal group, the mRNA levels of IL-6, IL-1β, TNF-α and TLR4 in the ovarian tissue of the model group were significantly increased (P<0.05, P<0.01). The Modified Guishen Wan group had significantly lower levels of IL-6, IL-1β and TLR4 mRNA compared to the model group (P<0.05), with a trend toward lower TNF-αmRNA levels (P＝0.188). Compared with the normal group, the protein expression of TLR4 in the ovarian tissue of the model group was significantly increased (P<0.05), and the phosphorylation levels of NF-κB p65 and IκBα were significantly elevated (P<0.05). The Modified Guishen Wan group had significantly lower TLR4 protein levels (P<0.05) and significantly reduced phosphorylation levels of NF-κB p65 and IκBα (P<0.05).

The Modified Guishen Wan may improve reproductive dysfunction and ovarian inflammation in PCOS rats by inhibiting the activation of the TLR4/NF-κB signaling pathway and reducing the production of inflammatory factors, providing new insights and theoretical basis for the clinical treatment of PCOS.

Cancer-associated fibroblasts (CAFs), which have the properties of myofibroblasts, are fibroblasts in tumor tissue that are activated by cancer cells and. CAFs can provide nutritional support and invasion channels for tumor cells, thereby helping tumor cell proliferation, invasion and metastasis. This paper observed the effect of Liujunzi Decoction (六君子汤) on the apoptosis of esophageal cancer-related CAFs and discussed its molecular mechanism, so as to provide experimental basis for the clinical application of Liujunzi Decoction in the treatment of esophageal cancer.

①The effect of TE-1 conditioned medium (TE-1M) on CAFs activity was detected by MTT method. ②The effect of Liujunzi Decoction on CAFs activity was detected by MTT method. ③The effects of Liujunzi Decoction on the secretion of transforming growth factor-β1 (TGF-β1) from CAFs were measured by ELISA. ④Flow cytometry was performed to detect the effect of Liujunzi Decoction on apoptosis of CAFs. ⑤The effects of Liujunzi Decoction on mRNA expression levels of CAFs apoptosis-related molecules were detected by RT-qPCR.6. The effects of Liujunzi Decoction on apoptosis-related molecular protein expression levels of CAFs were detected by Western Blot.

①The results of MTT showed that compared with the blank group, 50 μg/mL Liujunzi Decoction had no significant effect on the activity inhibition of CAFs, and the other concentration groups had an inhibitory effect on the activity of CAFs (P<0.05). ②The results of MTT showed that compared with the blank group, 10%, 20% and 30% TE-1M had a promoting effect on the proliferation of CAFs, among which 20% TE-1M had the most significant proliferation effect on CAFs (P<0.001), and 40% TE-1M (P<0.05) and 50% TE-1M (P<0.01) had a significant inhibitory effect on the proliferation of CAFs. ③The results of ELISA method showed that compared with the blank group, the content of TGF-β1 secreted by CAFs in the model group decreased (P<0.001), the content of TGF-β1 in the Liujunzi Decoction group was significantly increased (P<0.001), and the content of TGF-β1 in the SB-431542 inhibitor+Liujunzi Decoction group was decreased compared with that in the Liujunzi Decoction group (P<0.001). ④The results of flow cytometry showed that there was no significant difference in the apoptosis rate in the model group compared with that in the blank group. Compared with the model group, the apoptosis rate of the Liujunzi Decoction group was significantly increased (P<0.001), and the apoptosis rate of the SB-431542 inhibitor+Liujunzi Decoction group was significantly decreased compared with the Liujunzi Decoction group (P<0.001). ⑤The results of PCR showed that the expressions of Smad2 and FAP genes in the model group were increased (P<0.01, P<0.001) compared with those in the blank group, and the expressions of Smad2, Caspase-3 and FAP in the Liujunzi Decoction group were significantly increased (P<0.05, P<0.01, P<0.001) compared with those in the model group. Compared with those of the Liujunzi Decoction group, the expressions of Smad2, Caspase-3 and FAP in the were significantly decreased (P<0.05, P<0.001). ⑥The results of Western blot showed that compared with the blank group, the expression of Smad2 protein in the model group decreased (P<0.01). The expressions of Smad2 and Caspase-3 in the Liujunzi Decoction group were significantly increased (P<0.001) compared with those in the model group and the expression level of FAP protein was increased (P<0.05). Compared with those in the Liujunzi Decoction group, the expressions of Smad2 and Caspase-3 were significantly decreased in the SB-431542 inhibitor+Liujunzi Decoction group (P<0.01), and the expression of FAP protein was decreased (P<0.05).

The proliferation of CAFs was promoted by inhibiting TGF-β1/Smad2 pathway in indirect coculture with esophageal cancer cells. Liujunzi Decoction can induce CAFs apoptosis through TGF-β1/Smad2 pathway, and the induction effect of TGF-β1/Smad2 pathway on apoptosis of CAFs is more obvious in co-culture environment.

To optimize the fresh-cut process of Dahuang (Rheum officinale Baill.) using analytic hierarchy process (AHP) -CRITIC method.

Taking the total amount of water soluble extract, total anthraquinone and free anthraquinone as the chemical composition quality control indicators, AHP-CRITIC analysis was used to comprehensively score and analyze Dahuang (Rheum officinale Baill.) decoction pieces, combined with process parameters such as trait scoring, drying time and energy consumption, prepared by different processes and screen for the best process conditions.

The appearance traits scoring results showed that the S1-S3 sample groups all had the best trait of X3-X6 decoction pieces. Different cutting techniques had a significant impact on the chemical composition of Dahuang (Rheum officinale Baill.) decoction pieces, with the most significant difference being the content of free anthraquinone. According to the comprehensive evaluation results, in the S1 sample group, X3-X7>C, and X3-X7 was a unique group, indicating that there were quality differences among different medicinal herb groups. In group S2, X4-X8>C, with X4-X6 clustered into one group. In group S3, X2-X7>C, with X4-X7 clustered into one group, indicating a quality difference within the group.

Dahuang (Rheum officinale Baill.) with a thickness of 3 cm, dried to a moisture content of 47%-59%, cut 5 mm thick slices, and dried at 60℃. Compared with traditional techniques, the fresh cutting process has the advantages of simple procedures, time-saving and energy-saving, and high content of effective ingredients. This method is the best way to cut while fresh and has feasibility in the production of Dahuang (Rheum officinale Baill.) decoction pieces

To analyze the effects of Qili Qiangxin Capsule (芪苈强心胶囊) combined with Shakubatrivalsartan Sodium Tablets on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), fibrinogen (FIB), D-dimer (D-D) and vascular endothelial growth factor (VEGF) in the patients with chronic heart failure complicated with coronary heart disease, as well as the TCM syndromes and prognosis.

A total of 236 patients with chronic heart failure complicated with coronary heart disease admitted to the Fifth Affiliated Hospital of Xinjiang Medical University from January 2022 to March 2024 were divided into the combined group (118 cases) and the control group (118 cases) by simple random sampling. Both groups were treated with routine comprehensive treatment and Shakubatroxobin Sodium Tablets, while the combined group was treated with Qili Qiangxin Capsule. The course of treatment in both groups was 12 weeks. The changes of NT-proBNP, FIB, D-D and VEGF were detected before and after treatment, and the changes of cardiac function, 6-minute walking distance (6MWD) and TCM syndrome integral were evaluated, and the clinical prognosis of the two groups was evaluated after treatment.

After 12 weeks of treatment, the levels of NT-proBNP, FIB and D-D in both groups decreased, and VEGF increased. After 12 weeks of treatment, the levels of NT-proBNP, FIB and D-D in the combined group were lower than those in the control group, and the VEGF was higher than that in the control group (P<0.05). After 12 weeks of treatment, the levels of LVEF and CO in both groups increased, while the levels of LVEDD and LVESD decreased. After 12 weeks of treatment, the levels of LVEF and CO in the combined group were higher than those in the control group, and the levels of LVEDD and LVESD were lower than those in the control group (P<0.05). After 12 weeks of treatment, the results of 6MWD of both groups was higher than those before treatment, and the TCM syndrome integral was lower than that before treatment. After 12 weeks of treatment, the result of 6MWD of the combined group was higher than that of the control group, and its TCM syndrome score was lower than that of the control group (P<0.05). After 12 weeks of treatment, the total effective rate of the combined group was 87.29% (103/118), which was higher than that of the control group (66.95%, 79/118) (P<0.05).

Combined with Qili Qiangxin Capsule on the basis of Shakubatrivalsartan Sodium Tablets can effectively improve the levels of NT-proBNP, FIB, D-D and VEGF in the patients with chronic heart failure complicated with coronary heart disease, and is beneficial to the improvement of cardiac function, TCM syndrome score and prognosis.

Based on the external morphology and internal quality, the quality grading standards of Baizhu (Atractylodis Macrocephalae Rhizoma) medicinal materials and decoction pieces were established.

The external morphology and internal quality of Baizhu (Atractylodis Macrocephalae Rhizoma) medicinal materials and decoction pieces were measured respectively, and the correlation between external morphology and internal quality indexes was analyzed. Then, the medicinal materials and decoction pieces of Baizhu (Atractylodis Macrocephalae Rhizoma) were graded based on the external morphology, and the internal quality of different grades of medicinal materials and decoction pieces was determined. Through statistical analysis, the quality grading standard of the unity of external form and internal quality was established.

The correlation analysis of the external morphology and internal quality of Baizhu (Atractylodis Macrocephalae Rhizoma) showed that the length and single weight were significantly positively correlated with the content of volatile oil, the total amount of atractylenolide and the content of atractylone (P<0.05). The grade of Baizhu (Atractylodis Macrocephalae Rhizoma) was divided by length and single weight. It was found that the volatile oil content of second-class and third-class products was significantly different from that of first-class products (P<0.01), and there was a significant difference in atractylon content among the three grades (P<0.05, P<0.01 or P<0.000 1). Therefore, the contents of volatile oil and atractylon was used as a quantitative index for the classification of medicinal materials. The correlation analysis of the external morphology and internal quality of Baizhu (Atractylodis Macrocephalae Rhizoma) showed that the length was positively correlated with the content of volatile oil, the total amount of atractylenolide and the content of atractylon. The grade of Baizhu (Atractylodis Macrocephalae Rhizoma) decoction pieces was divided by length index, and it was found that the contents of volatile oil and atractylon were statistically significant between the two grades (P<0.000 1). Therefore, the content of volatile oil and atractylon was used as a quantitative index for the classification of decoction pieces.

The length, single weight and total amount of atractylenolide in the internal quality index of the appearance shape index were used as the comprehensive evaluation index of the internal and external quality of Baizhu (Atractylodis Macrocephalae Rhizoma). The diameter in the appearance shape index and the total amount of atractylenolide in the internal quality index were used as the comprehensive evaluation index of the internal and external quality of Baizhu (Atractylodis Macrocephalae Rhizoma). Considering the actual situation of the market, the classification standard of Baizhu (Atractylodis Macrocephalae Rhizoma) commodity specifications was formulated.

To study the effect of Huatan Huoxue Tongluo Decoction (化痰活血通络汤) on unstable angina pectoris of coronary heart disease and its effect on the serum levels of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP).

From January 2022 to December 2023, 100 patients with unstable angina pectoris of coronary heart disease treated in the hospital were selected and randomly divided into two groups, with 50 cases in each group. The control group was treated with enteric-coated aspirin and isosorbide dinitrate, while the observation group was additionally treated with Huatan Huoxue Tongluo Decoction on the basis of the control group. After 4 weeks of treatment, the TCM syndrome scores, angina attack conditions, cardiac function indicators, the serum levels of cTnI and NT-proBNP and medication safety were compared between the two groups.

After treatment, the TCM syndrome scores for chest tightness and heartache, shortness of breath and wheezing and palpitations with easy sweating significantly decreased in both groups, with the observation group showing greater improvement than the control group (P<0.05). After treatment, the Seattle Angina Questionnaire scores, the frequency of angina attacks and the duration of attacks decreased in both groups, with the observation group outperforming the control group (P<0.05). After treatment, both groups showed a significant reduction in left ventricular systolic and diastolic diameters and a significant increase in left ventricular ejection fraction, with the observation group outperforming the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of cTnI and NT-proBNP decreased in both groups, with a more significant decrease in the observation group (P<0.05). No serious adverse reactions occurred in either group during the treatment process.

The effect of Huatan Huoxue Tongluo Decoction in the treatment of unstable angina pectoris of coronary heart disease is satisfactory. It can effectively improve the main TCM syndromes of the patients, relieve the angina pectoris, improve the cardiac function and the serum levels of cTnI and NT-proBNP. It is a safe and effective medication plan.

To analyze the effects of Jiawei Huanglian Ejiao Decoction (加味黄连阿胶汤) on TCM syndrome scores, plasma levels of interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α), neuron-specific enolase (NSE) and sleep quality in the patients with sleep disorder after stroke.

One hundred and twenty patients with post-stroke sleep disorder admitted to the hospital from March 2021 to May 2023 were randomly divided into the combined group (60 cases) and the control group (60 cases). The two groups were treated with conventional drugs and transcranial magnetic stimulation, and the combined group was treated with Jiawei Huanglian Ejiao Decoction. Both groups were treated for 6 weeks. The TCM syndrome scores, plasma levels of IL-10, TNF-α and NSE and sleep quality of the two groups before and after treatment were compared, and the clinical value of the two treatment schemes was analyzed.

After 6-week treatment, the scores of symptoms such as soreness and weakness of the lower back knee, feverish sensation, dry mouth and throat, hot flashes and night sweats in both groups decreased compared with those before treatment, the scores of TCM syndromes in the combined group were lower than those in the control group, and the difference was statistically significant (P<0.05). After 6 weeks of treatment, the plasma IL-10 levels in the two groups increased, while the levels of TNF-α and NSE decreased, and the plasma IL-10 in the combined group was higher than that in the control group, and the levels of TNF-α and NSE were lower than those in the control group, with statistical significance (P<0.05). After 6 weeks of treatment, the scores of each factor and the total score of Pittsburgh sleep quality index (PSQI) scale in both groups decreased compared with those before treatment. The scores of all factors and the total score of PSQI in the combined group were lower than those in the control group, and the difference was statistically significant (P<0.05).

On the basis of routine drug treatment, Jiawei Huanglian Ejiao Decoction can improve the TCM syndrome score of the patients with sleep disorder after stroke, regulate the inflammatory reaction and promote the recovery of neurological function, which has a positive impact on the improvement of sleep quality of patients.

To investigate the therapeutic effect of Qingre Jieyu Decoction (清热解瘀汤) on the patients with thyroid nodules after ablation.

A hundred patients with thyroid nodules undergoing radiofrequency ablation treated in Guangdong Province Traditional Chinese Medical Hospital from June 2021 to June 2023 were included as the study objects, and were divided into two groups by the random number table method. Fifty patients in the control group were treated with conventional western medicine after radiofrequency ablation, and those in the observation group were treated with Qingre Jieyu Decoction after radiofrequency ablation. The therapeutic effects, symptom scores, maximum diameters and volumes of thyroid nodule, thyroid function indexes and so on of the two groups were compared.

After treatment, the total effective rate of the observation group was 96.0%, which was much higher than that of the control group (78.0%), and the scores of pain, swallowing discomfort, swelling and thermal swelling in the observation group were lower than those in the control group (P<0.05). After treatment, the nodule maximum diameter and nodule volume in the observation group were smaller than those in the control group, and the levels of serum thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4) after treatment were better than those in the control group (P<0.05).

The application of Qingre Jieyu Decoction after radiofrequency ablation for the patients with thyroid nodules can relieve heat and toxin, eliminate abscess and desiccation, effectively improve swallowing discomfort, swelling, pain and other symptoms of the patients after surgery, promote the reduction of thyroid nodules, improve the thyroid function and promote postoperative recovery as soon as possible.

To investigate the effects of Ginkgo biloba extract on the inflammatory response in the rats with ulcerative colitis (UC) based on the Toll-like receptor 4 (TLR4) /nuclear factor-κB (NF-κB) signaling pathway.

Forty SD rats were divided model group, Ginkgo biloba extract low-dose group, Ginkgo biloba extract high-dose group and normal group, each with 10 rats. The levels of interleukin (IL) -1 β, IL-6 and tumor necrosis factor (TNF) -α were measured using the Enzyme linked immunosorbent assay (ELISA) method. The expressions of TLR4 and NF-κB proteins in colon tissue was assessed via Western blot (WB). The Disease Activity Index (DAI), colon length, colon mucosal damage index (CMDI), inflammatory factors, TLR4 and NF-κB protein expressions were compared among the groups.

The DAI score, colon mucosal damage index (CMDI) score, the protein gray values of IL-1β, IL-6, TNF-α, TLR4 and NF-κB in the model group, Ginkgo biloba extract low-dose group and Ginkgo biloba extract high-dose group were higher than those of the normal group, while the colon length was shorter than that of the normal group (P<0.05). The DAI score, CMDI score, the protein gray values of IL-1β, IL-6,TNF-α, TLR4 and NF-κB of the Ginkgo biloba extract low-dose and high-dose groups were lower than those of the model group, while the colon length was longer than that of the model group (P<0.05). The DAI score, CMDI score, the protein gray values of IL-1β, IL-6, TNF-α, TLR4 and NF-κB of the Ginkgo biloba extract high-dose group were lower than those of the Ginkgo biloba extract low-dose group, while the colon length was longer than that of the low-dose Ginkgo biloba extract group (P<0.05).

Ginkgo biloba extract can alleviate the inflammatory response in the UC rats, and its mechanism may be related to the regulation of TLR4/NF-κB signaling pathway expression.

To investigate the clinical effect of Modified Longdan Xiegan Decoction (龙胆泻肝汤加减) combined with hepatic artery chemoembolization in the treatment of primary liver cancer complicated with portal vein cancer thrombus.

A total of 64 patients with primary liver cancer complicated with portal vein cancer thrombus admitted from January 2020 to January 2023 were included in the study and divided into into chemoembolization group (32 cases) and combined Chinese medicine group (32 cases) by random number table method. The patients in the chemoembolization group were treated with hepatic artery chemoembolization. Those in the combined Chinese medicine group were treated with Longdan Xiegan Decoction combined with hepatic artery chemoembolization, and the data of the patients in each group was observed, including the clinical efficacy, the changes in the total scores of TCM symptoms and the changes in the quality of life (QOL) before and after treatment, Eastern Cooperative Oncology Group (ECOG) scores, the changes of tumor markers such as Alpha-Feto protein (AFP), carcinoembryonic antigen (CEA), immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM), adverse reactions and 1-year survival rate.

The total effective rate of the combined Chinese medicine group was higher than that of the chemoembolization group (P<0.05). The total TCM syndrome scores, QOL score, ECOG score, tumor markers (AFP and CEA), immune function indexes (IgA, IgG, IgM) and other indexes were not significant between the two groups before treatment (P>0.05). After treatment, the total TCM syndrome scores, QOL score, ECOG score, tumor markers (AFP and CEA), immune function indexes (IgA, IgG, IgM) and other indexes were improved in both groups. These indexes in the combined Chinese medicine group were better than those in the chemoembolization group (P<0.05). The incidence of gastrointestinal discomfort and alopecia in the combined Chinese medicine group was lower than that in the chemoembolization group (P<0.05). The 1-year survival rate in the combined Chinese medicine group was higher than that in the chemoembolization group (P<0.05).

Modified Longdan Xiegan Decoction combined with hepatic artery chemoembolization has good clinical effect in the treatment of primary liver cancer complicated with portal vein cancer embolus, which can improve the patients'quality of life, immune ability and physical condition, reduce the rate of chemotherapy adverse reactions to a certain extent, and improve the 1-year survival rate of the patients.

To analyze the clinical effect of Qishen Yiqi Dripping Pill (芪参益气滴丸) combined with dapagliflozin and sacubitril-valsartan in the treatment of chronic heart failure.

A total of 206 patients with chronic heart failure with reduced ejection fraction who were admitted to Qinghai Special Hospital of Cardio-cerebrovascular Disease from June 2021 to June 2023 were selected and divided into control group (103 cases) and observation group (103 cases) by random number table method. The control group was treated with dapagliflozin and sacubitril-valsartan, and the observation group was treated with Qishen Yiqi Dripping Pill on the basis of the control group, and both groups were treated continuously for 8 weeks. The TCM syndrome scores, cardiac function index, serological index, 6 min walking test distance, quality of life, clinical efficacy and adverse reactions of the two groups were observed before and after treatment.

After 8 weeks of treatment, the TCM syndrome scores, the levels of left ventricular end-systolic diameter (LVESD), left ventricular end-diastolic diameter (LVEDD), hypersensitive C-reactive protein (hs-CRP), amino terminal brain natriuretic peptide precursor (NT-proBNP) and Minnesota Living with Heart Failure Quality of Life Questionnaire (MLHFQ) in the observation group were lower than those of the control group (P<0.05), and the levels of left ventricular ejection fraction (LVEF), cardiac output (CO) and left ventricular ejection fraction (LVEF) and 6 min walking test distance were lower than those of the control group (P<0.05). The total effective rate in the observation group was higher than that of the control group (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05).

The combination of Qishen Yiqi Dripping Pill and dapagliflozin and sacubitril-valsartan in the treatment of chronic heart failure can effectively alleviate the clinical symptoms, improve the cardiac function, reduce the inflammatory response and the risk of cardiac remodeling, enhance the cardiac reserve, increase the exercise tolerance and improve the quality of life of the patients, with clear efficacy and high safety.

To observe the clinical efficacy of acupuncture in the treatment of anorexia nervosa with cancer by regulating Du meridian and strengthening spleen, and to explore the mechanism of its action.

The cases were included from October 2022 to June 2024, and 80 patients with anorexia nervosa with carcinoma attending the Department of Medical Oncology of the hospital were divided into the conventional group and the acupuncture group, each with 40 cases, using the random number table method. The conventional group was treated with conventional treatment of tumor, and the acupuncture group was treated with the acupuncture method of regulating Du meridian and strengthening spleen on the basis of the conventional treatment of tumor, and was treated continuously for 6 weeks. Body mass, quantitative appetite scale (NRS) scores, functional assessment of anorexia/malassemia treatment (FAACT) scores and traditional Chinese medicine syndrome scores and the levels of tumour necrosis factor-alpha (TNF-α), haemoglobin, albumin, interleukin-6 (IL-6), orexin A and leptin were compared between the two groups before and after treatment for 3 and 6 weeks and the clinical effect was evaluated.

Before treatment, the differences in body mass, NRS scores, traditional Chinese medicine syndrome scores and FAACT scores were not statistically significant between two groups (P>0.05). Comparing 3 and 6 weeks of treatment with the pre-treatment period, the body mass and FAACT scores of the two groups increased, and the traditional Chinese medicine syndrome scores and NRS scores decreased (P<0.05). Comparing 3 and 6 weeks of treatment, the two groups had higher body mass and FAACT scores and lower traditional Chinese medicine syndrome scores and NRS scores than the conventional group (P<0.05). The differences in haemoglobin, albumin, TNF-α, IL-6, orexigenin A and leptin were not statistically significant between the two groups compared with those before treatment (P>0.05). Comparing 3 and 6 weeks of treatment with pre-treatment, the levels of haemoglobin, orexin A, albumin increased and TNF-α, IL-6 and leptin decreased in both groups (P<0.05) and those levels in the acupuncture group were significantly lower compared with those in the conventional group (P<0.05). The total effective rate of the acupuncture group (87.50%) was higher than that of the conventional group (67.50%), and the difference was statistically significant (P<0.05).

Acupuncture treatment of cancerous anorexia nervosa with the method of regulating Du meridian and strengthening spleen improves the nutritional status of the body and enhances the therapeutic efficacy, which may be related to the regulation of the neuro-endocrine network.

To explore the effect of Shugan Huayu Jieyu Decoction (疏肝化瘀解郁汤) combined with acupuncture on post-stroke depression and its influence on patients'physical and mental health.

A total of 119 patients with post-stroke depression admitted to the hospital from December 2020 to November 2023 were divided into groups by random number table method, and the patients were divided into western medicine group (59 cases) and traditional Chinese medicine group (60 cases). The patients in the western medicine group were treated with fluoxetine hydrochloride, and those in the traditional Chinese medicine group were treated with Shugan Huayu Jieyu Decoction combined with acupuncture therapy. The clinical efficacy and adverse reactions, traditional Chinese medicine symptom scores (depression, loss of interest, irritability, slow thinking, insomnia, fatigue, etc.) before and after treatment, Hamilton depression scale (HAMD) score and National Institute of Health stroke scale (NIHSS) score, the levels of norepinephrine (NE) and 5-hydroxytryptophan (5-HT), Pittsburgh sleep quality index (PSQI) and activities of daily living (ADL) scores of two groups were compared.

The total effective rate of traditional Chinese medicine group was 96.67%, which was higher than that of western medicine group (86.44%) (P<0.05). The adverse reaction rates of traditional Chinese medicine group and western medicine group were 3.33% and 3.39%, respectively, which were more tolerable by patients (P>0.05). Before treatment, traditional Chinese medicine syndrome scores (depression, loss of interest, irritability, slow thinking, insomnia, fatigue, etc.), HAMD score, NIHSS score, the levels of NE and 5-HT, PSQI score and ADL score were not significant in two groups (P>0.05). After treatment, traditional Chinese medicine syndrome scores (depression, loss of interest, irritability, slow thinking, insomnia, fatigue, etc.), HAMD scores, NIHSS scores, the levels of NE and 5-HT, PSQI scores and ADL scores were improved in two groups. After treatment, these indexes in traditional Chinese medicine group were all better than those in western medicine group (P<0.05).

The combination of Shugan Huayu Jieyu Decoction and acupuncture in the treatment of post-stroke depression is significant, safe and reliable.

To investigate the clinical effect of Modified Sijunzi Decoction (四君子汤加减) combined with FOLFOX4 in the treatment of primary gastric cancer.

A total of 98 patients with primary gastric cancer admitted from January 2021 to April 2024 were included in the study and divided into FOLFOX4 regimen group and combined Chinese medicine group by random number table method. All patients in FOLFOX4 regimen group (49 cases) were treated with FOLFOX4 chemotherapy regimen. The patients in the combined Chinese medicine group (49 cases) were treated with Sijunzi Decoction combined with FOLFOX4 regimen. The data of each group was compared, including the clinical efficacy, stomach intake or poor appetite, abnormal stool, lack of thirst, continuous abdominal pain or warm preference, intestinal distress and other traditional Chinese medicine syndrome score changes, the levels of gastrin (GAS), pepsinogen Ⅰ (PGⅠ) and pepsinogen Ⅱ (PGⅡ), the levels of gastrointestinal hormone, carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA), changes in T cell subsets such as CD3⁺, CD4⁺, CD8⁺ and adverse reactions to chemotherapy.

The total effective rate of the combined Chinese medicine group was higher than that of FOLFOX4 regimen group (P<0.05). Before treatment, the two groups of patients with decreased stomach intake or poor appetite, abnormal stool, lack of thirst, continuous abdominal pain or traditional Chinese medicine syndrome scores, gastrointestinal hormone levels (GAS, PGⅠ, PGⅡ), tumor marker levels (CA125, CEA), CD3⁺, CD4⁺, CD8⁺ and other indicators were not significant (all P>0.05). After treatment, the combined Chinese medicine group were better than those in the FOLFOX4 group in terms of reduced stomach intake, poor appetite, abnormal stool, lack of thirst, continuous abdominal pain, warm preference, colon distress, gastrointestinal hormone level (GAS, PGⅠ, PGⅡ), tumor marker levels (CA125, CEA), CD3⁺, CD4⁺, CD8⁺ and other indicators (P<0.05). The incidence of gastrointestinal discomfort in the combined Chinese medicine group was lower than that in the FOLFOX4 regimen group (P<0.05).

Sijunzi Decoction combined with FOL-FOX4 has good clinical effect in the treatment of primary gastric cancer, which can effectively reduce the levels of tumor markers, improve the disease and gastrointestinal hormone levels, improve the immune function of patients and reduce some adverse reactions, and the treatment is safe and reliable.

To observe the efficacy and safety of Dengzhan Shengmai Capsule (灯盏生脉胶囊) combined with repeated transcranial magnetic stimulation in the treatment of vascular dementia after cerebral infarction.

A total of 69 patients with vascular dementia after cerebral infarction admitted from May 2021 to December 2023 were included in the study, and the patients were divided into control group and observation group by random number table method. The patients in the control group (34 cases) received conventional clinical treatment plus repeated transcranial magnetic stimulation treatment, and the observation group (35 cases) received combined treatment with Dengzhan Shengmai Capsule on the basis of the treatment in the control group, both groups were treated for 2 months. The efficacy and adverse reactions, the changes in TCM symptom scores, the levels of nerve growth factor (NGF), neuron-specific enolase (NSE) and brain-derived neurotrophic factor (BDNF) and blood flow velocity changes in anterior cerebral artery (ACA), middle cerebral artery (MCA) and posterior cerebral artery (PCA), left and right vertebral artery (VA), and Hasegawa dementia scale (HDS) and Mini-Mental State Examination (MMSE) scores before and after treatment were observed.

The total effective rate of the observation group was higher than that of the control group (P<0.05). No serious adverse reactions were observed in observation group and control group (P>0.05). Traditional Chinese medicine syndrome scores, the levels of NGF, NSE and BDNF, the blood flow velocities of ACA, MCA, PCA and VA, HDS score and MMSE score were not significant between the two groups before treatment (P>0.05). After treatment, the TCM syndrome scores, the levels of NGF, NSE and BDNF, the blood flow velocities of ACA, MCA, PCA and VA, HDS score and MMSE score were significantly improved in both groups. These indexes in the observation group were better than those in the control group (P<0.05).

Dengzhan Shengmai Capsule combined with repeated transcranial magnetic stimulation has good efficacy in the treatment of vascular dementia after cerebral infarction and can improve the symptoms, cognitive function, cerebral blood flow and nerve function of the patients.

To observe the therapeutic effect of Wenzhong Jianpi Decoction (温中健脾汤) on chronic atrophic gastritis (deficiency of spleen and stomach syndrome) and its impact on the levels of calcitonin gene related peptide (CGRP), epidermal growth factor (EGF) and gastrointestinal hormone endothelin (ET).

Ninety patients with chronic atrophic gastritis with deficiency of spleen and stomach syndrome met the inclusion criteria for this study were randomly divided into two groups using a random number table method. The control group received symptomatic treatment with conventional Western medicine, while the observation group was additionally treated with Wenzhong Jianpi Decoction orally. After 8 weeks of continuous treatment, the pathological scores (atrophy, intestinal metaplasia, dysplasia, chronic inflammation and motility), the gastric mucosal blood flow (anterior and posterior walls of gastric antrum, greater and lesser curvature of gastric antrum) and the serum levels of gastrointestinal hormones (ET, CGRP, EGF) before and after treatment between the two groups were compared, and the total effective rate and drug safety of the two groups were also observed.

After treatment, the scores of atrophy, intestinal metaplasia, dysplasia, chronic inflammation and activity, the serum levels of ET and EGF in both groups were lower than those before treatment (P<0.05), which in the observation group were lower than those in the control group (P<0.05). After treatment, the serum levels of CGRP and the blood flow of the anterior and posterior walls of the gastric antrum, the greater curvature of the gastric antrum and the lesser curvature of the gastric antrum in both groups were higher than those before treatment (P<0.05), which in the observation group were higher than those in the control group (P<0.05). The total effective rate of the observation group (91.1%, 41/45) was higher than that of the control group (73.3%, 33/45) (P<0.05). There were no adverse reactions related to medication during the treatment in both groups.

The application of Wenzhong Jianpi Decoction can regulate the serum levels of CGRP, EGF and ET in the patients with chronic atrophic gastritis with deficiency of spleen and stomach syndrome and increase the gastric mucosal blood flow, which help to improve gastric pathological status and enhance the treatment effectiveness.

To observe the safety and efficacy of Xuezhikang (血脂康) in combination with proprotein convertase subtilisin/kexin type 9 (PCSK9i) in the treatment of the patients with statin-intolerant coronary atherosclerotic heart disease (coronary artery disease).

A total of 104 cases of statin-intolerant coronary heart disease patients admitted to the Department of Cardiology of the Affiliated Hospital of Jilin Medical University from 2023.2 to 2024.2 were selected as the study population, and were divided into the routine group and the Xuezhikang group using the lottery method, and both groups were given coronary heart disease secondary preventive drug treatment, 52 cases in the routine group were given iloyuzumab treatment, 52 cases in the Xuezhikang group were given Xuezhikang Capsule combined with iloyuzumab treatment, and both groups were continuously treated for half a year. The lipid levels of the two groups before treatment, after 1, 3 and 6 months of treatment were compared. The levels of PCSK9, cholesterol ester transfer protein (CETP), apolipoprotein B (ApoB), cardiac function, 6-minute walk test, glutamic acid aminotransferase (ALT), glutamine transaminase (AST), creatine kinase isoenzymes (CK-MB) and traditional Chinese medicine syndrome scores in the two groups before treatment and after 6 months of treatment were compared. The cumulative endpoint events in both groups within six months were counted.

There was no difference in the levels of lipid indexes before treatment between the two groups (P>0.05). The levels of total cholesterol (TG), triglyceride (TC) and low-density lipoprotein cholesterol (LDL-C) after 1, 3 and 6 months of treatment in both groups were lower than those before treatment, and the levels of TG, TC and LDL-C in the Xuezhikang group were lower than those of the routine group after 1, 3 and 6 months of treatment (P<0.05). Comparison of high-density lipoprotein cholesterol (HDL-C) levels after 1, 3 and 6 months of treatment in the two groups showed no difference (P>0.05). Comparison of PCSK9, CETP, ApoB, AST, ALT, and CK-MB levels before treatment between the two groups showed no difference (P>0.05). The levels of PCSK9, ApoB, AST, ALT and CK-MB were lower than those before treatment after 6 months of treatment in both groups, and the levels of PCSK9 and ApoB in the Xuezhikang group were lower than those in the routine group after 6 months of treatment (P<0.05). There was no difference in the levels of CETP, AST, ALT or CK-MB after 6 months of treatment between the two groups (P>0.05). Comparison of cardiac function and 6-minute walk test levels before treatment between the two groups showed no difference (P>0.05). The levels of left ventricular ejection fraction (LVEF), cardiac output (CO) and 6-minute walk test were higher in both groups after 6 months of treatment compared with the pre-treatment levels, and the levels of LVEF, CO and 6-minute walk test were higher in the Xuezhikang group than those in the routine group after 6 months of treatment (P<0.05). The levels of left ventricular end-diastolic internal diameter (LVESD) were lower in both groups after 6 months of treatment than those before treatment, and the levels of LVESD were lower in the Xuezhikang group than those in the routine group after 6 months of treatment (P<0.05). Comparison of cumulative endpoint events between the two groups showed no difference (P>0.05). Before treatment, there was no difference in traditional Chinese medicine syndrome scores between the two groups (P>0.05). The scores of the two groups after 6 months of treatment were lower than those before treatment, and the score of the Xuezhikang group was lower than that of the routine group (P<0.05).

Xuezhikang combined with PCSK9 inhibitor for statin-intolerant coronary artery disease can regulate the lipid metabolism and improve the cardiac function with high safety.

To observe the clinical effect of Tiaoying Yiwei Prescription (调营益卫方) combined with XELOX in the treatment of advanced colorectal cancer.

A total of 60 patients with advanced colorectal cancer admitted from October 2022 to December 2023 were included in this study. The patients were divided into observation group and control group by random number table method, with 30 patients in each group. The patients in the control group were treated with XELOX regimen, while those in the observation group were treated with XELOX regimen+Tiaoying Yiwei Prescription. Before and after treatment, the treatment effect, the TCM symptom scores (fatigue, dry or loose stools, abdominal pain, sallow complexion, and emaciation), the serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA199), carbohydrate antigen (CA242), T lymphocyte subsets and natural killer (NK) cell changes, adverse reactions, bowel cancer survival quality score (Functional Assessment of Cancer Therapy: Colorectal Cancer, FACT-C4.0 Chinese version) and physical condition Karnofsky Performance Status (KPS) score changes of two groups were compared.

The total effective rate between the control group and the observation group was significant (46.67% vs 73.33%) (P<0.05). Before treatment, the scores of TCM symptoms (fatigue, dry or loose stools, abdominal pain, sallow complexion, and emaciation), the levels of CEA, CA199, CA242, CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺, NK indicators, KPS scores, and survival quality scores in each group were not significant (P>0.05). After treatment, the scores of TCM symptoms (fatigue, dry or loose stools, abdominal pain, sallow complexion, and emaciation), the levels of CEA, CA199 and CA242 decreased in each group, while the KPS scores and survival quality scores improved. The scores of TCM symptoms (fatigue, dry or loose stools, abdominal pain, sallow complexion and emaciation), the levels of CEA, CA199 and CA242 in the observation group were lower than those in the control group after treatment, while the KPS scores and survival quality scores were higher than those in the control group (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and NK indicators in the control group decreased, while those in the observation group increased. The comparison of CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺ and NK indicators between the two groups after treatment showed significance (P<0.05). The incidence of chemotherapy-related adverse reactions such as nausea and vomiting, loss of appetite, hair loss and diarrhea was lower in the observation group than that in the control group (P<0.05).

Tiaoying Yiwei Prescription combined with XELOX regimen has significant efficacy in the treatment of advanced colorectal cancer, which can improve the clinical symptoms, immune function and quality of life of thr patients, and also reduce some side effects of patients. It is safe and worthy of application.